Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 51Specimen Handling 42enzalutamide 36Androgen Antagonists 35Radiosurgery 33Radiotherapy 31darolutamide 26Prednisone 26Abiraterone Acetate 25Leuprolide 22Docetaxel 22apalutamide 21abiraterone 19Pluvicto 19Standard of Care 18Triptorelin Pamoate 17Radiation 17Biopsy 16relugolix 15acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 14Blood Specimen Collection 13gallium 68 PSMA-11 12X-Rays 11Surveys and Questionnaires 11pembrolizumab 10luprolide acetate gel depot 10Carboplatin 10Methods 9Interviews as Topic 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms × 18-O-demethylcervinomycin A2 × Clear all
NCT07179783 2025-09-18

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Tianjin Medical University Second Hospital

Phase 2 Recruiting
28 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡